Swiss pharmaceutical group Roche has reported a four per cent increase in full-year net profit to SFr8.89 billion ($9.52 billion) in 2010.
This content was published on
1 minute
swissinfo.ch and agencies
Growth in sales of Roche’s anti-cancer drugs was unable to compensate for a drop in sales of the group’s Tamiflu treatment and the surge in the Swiss franc. Full-year sales fell by three per cent to SFr47.47 billion, according to figures published on Wednesday.
Commenting on the Basel-based group’s performance, CEO Severin Schwan said the results were “solid despite an increasingly challenging market environment”.
Roche said it expects healthcare reforms in the United States and European austerity measures to dampen growth in 2011.
The group is hoping to save SFr1.8 billion in 2011 through a restructuring plan announced in November.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche cuts 4,800 jobs as market feels squeeze
This content was published on
The Basel-based multinational aims to save SFr2.4 billion ($2.42 billion) a year by reducing its workforce by 4,800 and outsourcing another 700 positions. Share prices rose on the announcement, but analyst reaction was mixed. The “Operational Excellence Program” unveiled on Wednesday came as no great surprise as Roche had earlier given strong hints that it…
This content was published on
Roche, which already owns 56 per cent of the biotech firm, will buy the remaining stake if Genentech shareholders end a protracted takeover battle by agreeing to a $46.8 billion (SFr54 billion) valuation. News of the agreement between the two company boardrooms came after an unsuccessful Roche offer last year followed by a lower hostile…
This content was published on
Jurors in New Jersey awarded the complainant $2.6 million (SFr3.2 million) after finding that the company had failed to adequately warn patients of the disease risk. This failure contributed to the complainant contracting the condition, said the jury. Andrew McCarrell, a 36-year-old manager from Alabama, won $119,000 to cover past medical expenses and $2.5 million…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.